Conference Details - Overview
Ninth International Congress on Targeted Therapies in Cancer
L’Enfant Plaza Hotel
Washington, DC
August 20-22, 2010
Conference Overview
Overview and Purpose
The Ninth International Congress on Targeted Therapies in Cancer is designed to provide participants with cutting-edge information on novel targeted anticancer therapies now in development, including the most current clinical data on those agents as well as information on their mechanisms of action. The congress will provide a unique opportunity for medical oncologists, translational researchers, and those engaged in drug development to learn from and interact with international leaders in novel therapeutic and drug discovery platforms and to obtain a preview of agents in development for the next generation of cancer therapy. Topics to be discussed include DNA repair and PARP inhibition, the tumor microenvironment, cell surface receptors, mediators of intracellular signaling, regulators of cellular processes such as protein homeostasis and apoptosis, and novel immunotherapeutic agents being developed in multiple tumor types.
Target Audience
This educational program is directed toward medical oncologists, translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. Other health care professionals interested in the treatment of cancer are also invited to attend.
Learning Objectives
At the conclusion of this congress, you should be able to:
- Discuss approaches to target the tumor microenvironment for cancer therapy
- Describe approaches to inhibit DNA repair and disrupt the cell cycle in cancer cells
- Evaluate data on inhibitors of novel signaling pathways in cancer therapy
- Assess the role of new imaging techniques in drug delivery and monitoring response
- Evaluate strategies to induce apoptotic signaling in tumor cells
- Appraise new approaches to develop immunotherapeutic agents in cancer therapy
- Discuss approaches to target protein homeostasis for cancer therapy
- Identify appropriate clinical trials of novel targeted agents that benefit specific groups of patients with cancer
Meeting information is accurate at the time of posting.
110-2557